12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

DSC127: Phase III started

Derma Sciences began the first of 2 North American Phase III trials of a 0.03% formulation of DSC127 once daily for 4 weeks in about 1,055 total patients with chronic, non-healing diabetic foot ulcers. The first trial will compare DSC127 vs. a topical vehicle. The second trial, which is...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >